Baietto Lorena, D'Avolio Antonio, De Rosa Francesco Giuseppe, Garazzino Silvia, Patanella Samantha, Siccardi Marco, Sciandra Mauro, Di Perri Giovanni
Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Turin, Italy.
Ther Drug Monit. 2009 Feb;31(1):104-9. doi: 10.1097/FTD.0b013e31819476fa.
A high-performance liquid chromatography method with UV detection was developed and validated for the simultaneous quantification of linezolid (LZD), rifampicin (RFP), levofloxacin (LEVO), and moxifloxacin (MOXI) in human plasma. The method is based on a simple organic protein precipitation that guarantees rapid sample preparation and a direct injection into the high-performance liquid chromatography system. The use of quinoxaline as internal standard improved accuracy (relative standard deviation, RSD% <14.9%) and precision (RSD% <14.3%). The recovery was 75.9% (RSD% = 5.8). The limits of quantification were 0.234 microg/mL for LEVO, 0.312 microg/mL for LZD, 0.156 microg/mL for MOXI, and 0.622 microg/mL for RFP. This method allows the simultaneous measurement of LEVO, LZD, MOXI, and RFP in human plasma and may be used for both routine clinical applications and pharmacokinetic studies.
建立了一种采用紫外检测的高效液相色谱法，并对其进行了验证，用于同时定量测定人血浆中的利奈唑胺（LZD）、利福平（RFP）、左氧氟沙星（LEVO）和莫西沙星（MOXI）。该方法基于简单的有机蛋白沉淀法，可确保快速的样品制备并直接进样到高效液相色谱系统中。使用喹喔啉作为内标提高了准确性（相对标准偏差，RSD%<14.9%）和精密度（RSD%<14.3%）。回收率为75.9%（RSD%=5.8）。LEVO的定量限为0.234μg/mL，LZD为0.312μg/mL，MOXI为0.156μg/mL，RFP为0.622μg/mL。该方法可同时测定人血浆中的LEVO、LZD、MOXI和RFP，可用于常规临床应用和药代动力学研究。
